Low-molecular-weight heparin in thrombophilic women receiving in vitro fertilization/intracytoplasmic sperm injection : A meta-analysis

© 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)..

INTRODUCTION: This meta-analysis aimed to evaluate the efficacy and safety of low-molecular-weight heparin (LMWH) on pregnancy outcomes in thrombophilic women receiving in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI).

MATERIAL AND METHODS: A systematic literature search of PubMed, EMBASE, the Cochrane Library, and China National Knowledge Infrastructure was performed to identify randomized controlled trials (RCTs) comparing LMWH with no treatment or placebo published from database inception until February 19, 2023. Primary outcomes were the clinical pregnancy rate and implantation rate, and secondary outcomes were the live birth rate, miscarriage rate, and the risk of bleeding events. The certainty of the evidence was rated using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system. Meta-analysis was conducted using STATA 14.0.

RESULTS: Five RCTs involving 1094 thrombophilic women receiving IVF/ICSI were finally included. Administration of LMWH was associated with statistically higher clinical pregnancy rate (4 RCTs, risk ratio [RR] 1.50, 95% confidence interval [CI] 1.23-1.82, p < 0.001, low certainty evidence), implantation rate (5 RCTs, RR 1.49, 95% CI 1.25-1.78, p < 0.001, very low certainty evidence), and live birth rate (2 RCTs, RR 2.15, 95% CI 1.60-2.89, p < 0.001, very low certainty evidence), but with statistically lower miscarriage rate (2 RCTs, RR 0.36, 95% CI 0.15-0.86, p = 0.021, very low certainty evidence). However, using LMWH was linked to a higher risk of bleeding events (2 RCTs, RR 2.36, 95% CI 1.49-3.74, p < 0.001, very low certainty evidence).

CONCLUSIONS: Very low certainty evidence suggests that administration of LMWH may benefit pregnancy outcomes in thrombophilic women receiving IVF/ICSI treatment, although it may also increase the risk of bleeding events. However, before putting our findings into practice, healthcare professionals should conduct an in-depth evaluation of the available evidence and specific patient situations. Furthermore, due to the low methodological quality of the included studies, more high-quality studies are needed to validate our findings in the future.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:102

Enthalten in:

Acta obstetricia et gynecologica Scandinavica - 102(2023), 11 vom: 20. Nov., Seite 1431-1439

Sprache:

Englisch

Beteiligte Personen:

Chen, Jingsi [VerfasserIn]
Bie, Jia [VerfasserIn]
Jiang, Fangjie [VerfasserIn]
Wu, Yanzhi [VerfasserIn]
Pan, Zhengmei [VerfasserIn]
Meng, Yushi [VerfasserIn]
Song, Jiamei [VerfasserIn]
Liu, Yang [VerfasserIn]

Links:

Volltext

Themen:

Heparin, Low-Molecular-Weight
In vitro fertilization
Intracytoplasmic sperm injection
Journal Article
Low-molecular-weight heparin
Meta-Analysis
Pregnancy outcomes
Review
Thrombophilia

Anmerkungen:

Date Completed 23.10.2023

Date Revised 24.10.2023

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1111/aogs.14634

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM359756204